Industry Welcomes Australia’s OTC Drug Approach To Low-Dose CBD
Australia's Therapetics Goods Administration finalizes its decision to regulate low-dose CBD as an OTC medicine, raising the maximum daily dose to 150mg. The move is welcomed by the country's self-care industry.
You may also be interested in...
GSK will evaluate the launch potential in Australia of a non-prescription CBD product currently being studied as a short-term treatment for sleep disturbances. The firm also has first refusal to negotiate the rights to market the product – developed by Cann Group – in other countries around the world.
[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.
A wide-ranging study of low-dose cannabidiol supplementation, its regulation, efficacy and safety calls for improved legislation, guidelines and quality control together with clinical trials exploring the increasingly popular ingredient's therapeutic benefits.